D
Diego Cortinovis
Researcher at University of Milano-Bicocca
Publications - 192
Citations - 8353
Diego Cortinovis is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 29, co-authored 147 publications receiving 6055 citations.
Papers
More filters
Journal ArticleDOI
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more
TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.
Journal ArticleDOI
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria,Daniel Shao-Weng Tan,Rita Chiari,Yi-Long Wu,Luis Paz-Ares,Juergen Wolf,Sarayut Lucien Geater,Sergey Orlov,Diego Cortinovis,Chong-Jen Yu,Maximillian Hochmair,Alexis B. Cortot,Chun-Ming Tsai,Denis Moro-Sibilot,Rosario Garcia Campelo,Tracey McCulloch,Paramita Sen,Margaret Dugan,Serafino Pantano,Fabrice Branle,Cristian Massacesi,Gilberto de Castro +21 more
TL;DR: First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC.
Journal ArticleDOI
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools
Guido Cavaletti,Barbara Frigeni,Francesca Lanzani,Laura Mattavelli,E Susani,Paola Alberti,Diego Cortinovis,Paolo Bidoli +7 more
TL;DR: In this review, the available data regarding the different tools used to assess CIPN will be revised and their features will be critically examined, with a special focus on their reliability and reproducibility across examiners and, when available, through direct comparison.
Journal ArticleDOI
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Louis Fehrenbacher,Joachim von Pawel,Keunchil Park,Achim Rittmeyer,David R. Gandara,Santiago Ponce Aix,Ji Youn Han,Shirish M. Gadgeel,Toyoaki Hida,Diego Cortinovis,Manuel Cobo,Dariusz M. Kowalski,Filippo de Marinis,M. Gandhi,Bradford Danner,C. Matheny,Marcin Kowanetz,Pei He,Federico Felizzi,Hina Patel,Alan Sandler,Marcus Ballinger,Fabrice Barlesi +22 more
TL;DR: The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel and continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.
Journal ArticleDOI
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
Andreas A. Argyriou,Guido Cavaletti,Chiara Briani,Roser Velasco,Jordi Bruna,Marta Campagnolo,Paola Alberti,Francesca Bergamo,Diego Cortinovis,Marina Cazzaniga,Cristina Santos,Konstantinos Papadimitriou,Haralabos P. Kalofonos +12 more
TL;DR: The objective of the current prospective, multicenter, international study was to trace the incidence and severity of acute oxaliplatin‐induced peripheral neuropathy (OXLIPN) and to determine its clinical pattern.